Swetha Kambhampati
@swethakmd
Assistant Professor at City of Hope; Alum: UCSF heme/onc, Hopkins IM, Stanford Med; Interested in lymphoma and CART
ID: 116636775
23-02-2010 04:20:47
285 Tweet
475 Takipçi
277 Takip Edilen
Pola-R-CHP can be more cost-effective than R-CHOP in patients with treatment-naïve DLBCL in certain circumstances, according to an analysis by Swetha Kambhampati, of City of Hope. bloodcancerstoday.com/post/polatuzum…
#Tandem23 | Swetha Kambhampati of City of Hope discusses real-world outcomes of patients with transformed R/R DLBCL treated with CAR-T therapy: 👉ow.ly/Hsb550N5GV4👈 ASTCT CIBMTR #DLBCL #LymSM #CARTcell #ImmunoOnc
Great group at the LRF Sci Res Mentoring Program in Las Vegas Carla Casulo, MD Swetha Kambhampati
Phenomenal and inspirational week at LRF LSRMP! great mentorship and developed life long friendships and connections! Grateful for the experience Lymphoma Research Foundation City of Hope
Excited the City of Hope experience with bridging therapy prior to CAR T for LBCL is published. Thanks for the collaboration between City of Hope - Department of Radiation Oncology and City of Hope Department of Medical Oncology. Stay tuned for our prospective trial shortly! mdpi.com/2072-6694/15/6…
🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host chadi nabhan MD, MBA, FACP speaking with Swetha Kambhampati of City of Hope and Nikhil Thiruvengadam, MD, of UC San Francisco about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies. Society of Hematologic Oncology (SOHO)
Dr. Ayushi Chauhan Ayushi Chauhan from Georgia Cancer Center named the 2023 Stephanie A. Gregory Distinguished Scholar by the Lymphoma Research Foundation Lymphoma Research Foundation. A brilliant young investigator. Very proud of her accomplishments.
🔊OUT NOW: This all-new episode of The HemOnc Pulse features host chadi nabhan MD, MBA, FACP speaking with Swetha Kambhampati of City of Hope and Nikhil Thiruvengadam, MD, about the cost effectiveness of pola-R-CHP in relation to other therapies for DLBCL. Society of Hematologic Oncology (SOHO) bloodcancerstoday.com/podcast/what-i…
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in patients with relapsed or refractory LBCL, according to the primary OS analysis of the phase III ZUMA-7 study released by Kite, a Gilead Company. bloodcancerstoday.com/post/zuma-7-su…
Developing the treatments of tomorrow is hard work. Dr. Amrita Krishnan, M.D., and L. Elizabeth Budde, M.D., Ph.D., M.D., Ph.D., are leading a few clinical trials related to bispecific antibodies and their ability to target cancer cells more precisely than chemo. bit.ly/3LTlAoi #HemOnc
When's public ARB maron Evan Norman Homelander Thành Nguyễn Đừng Nhấn Vào Đây Champ N @elekxmiki Kidmon ❤️ Memecoin Kinobe @Kriptoagatmi
I just went into beta its so FIRE Bronson SlumDogMillionaire Connie Giles clemontinnel @Hutchin95272841 Mauro Soso The human meng(💙,🧡)
Im SHIB for always Nidhi саша алекс Emerald (🌸, 🌿).bnb @LLove6688 ミミ.lens＠レム大好き(🌸, 🌿) 🛸 Aysha Paul van Tunes andrei 🦇🔊
Chilling with my ARB reimbursement money Who is She? ABDULAZEEZ LAWAN "🐉 $MON" NYAN🔫 $TEMPLE ❤️ Xally @michael27677957 Mindy Spurlock Howard Tuấn Minh Nino369 Hoa Trong Tuyết REKT007 (✸,✸) (🔟/🔟)#REVA ( )
Im SHIB for always julian nunez Liv K Crypto Samurai @Crofwgkta @rost_1989 Ruben Diaz BitMore VINCCIROM.Ξ
I got my ARB losses back. Dominick Loyd NUSRAT PRAWEEN Rania Ismaya Keerthi Geeth Kumara 🐉 $MON" ❤️ $BLOCK @seriouscawcaw SadracChora $XTER Mazhar Kazmi Blessroth